ArticleAging2020
B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Association of B3GNT3 Expression with Tumour Stage and Lymph Node Metastasis in Colon Adenocarcinoma.International journal of molecular sciences · 2026Article
- A Prognostic Risk Model Based on Immune Genes in Thyroid Cancer and Its Correlation With Tumor-Associated Immune Cell Infiltration Abundance.Cancer medicine · 2026Article
- Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer.Discover oncology · 2026Review
- Immunohistochemical expression of CANT1 and B3GNT3 in invasive ductal carcinoma of the breast: diagnostic and prognostic significance in lymph node metastasis.Diagnostic pathology · 2026Article
- Charting the immune terrain: a novel risk model for thyroid cancer prognosis.Frontiers in genetics · 2026Article
- Article
- Article
- Impacts of β-1, 3-N-acetylglucosaminyltransferases (B3GNTs) in human diseases.Molecular biology reports · 2024Review
- Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer.American journal of cancer research · 2024Article
- ETV4 facilitates proliferation, migration, and invasion of liver cancer by mediating TGF-β signal transduction through activation of B3GNT3.Genes & genomics · 2023Article
- Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma.Cell death and differentiation · 2023Article
- Experimental study on the suppressive effect of B3GNT3 on the apoptosis of lung adenocarcinoma cells and its application in early screening for lung adenocarcinoma.Journal of thoracic disease · 2023Article
- The role of B3GNT3 as an oncogene in the growth, invasion and migration of esophageal cancer cells.Acta cirurgica brasileira · 2023Article
- Review
- Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq.Cancer immunology, immunotherapy : CII · 2022Article
- B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma.Annals of translational medicine · 2022Article
- B7 family protein glycosylation: Promising novel targets in tumor treatment.Frontiers in immunology · 2022Review
- SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression.Journal of hepatocellular carcinoma · 2022Article
- Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta-1,3-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.